FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Chimerix NDA for Glioma Drug

[ Price : $8.95]

Chimerix files an NDA seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diff...

Temple Retires; Bumpus Leaves FDA

[ Price : $8.95]

CDER senior advisor for clinical science Bob Temple retires, and FDA principal deputy commissioner Namandj Bumpus leaves the agenc...

Xbrane Refiles Lucentis Biosimilar BLA

[ Price : $8.95]

Xbrane Biopharma refiles a BLA for its investigational ranibizumab, a biosimilar copy of Genentechs age-related macular degenerati...

Alert on AquaFlexFlow Blood Circuits

[ Price : $8.95]

FDA issues a safety alert on Nuwellis AquaFlexFlow UF 500 Plus extracorporeal blood circuit because the device may trigger a weigh...

Senators Introduce Skinny Label Generic Drug Bill

[ Price : $8.95]

Four senators introduce bipartisan legislation to protect generic drug manufacturers from innovator drug lawsuits over skinny labe...

CRL for Zealands SBS Treatment NDA

[ Price : $8.95]

FDA issues a complete response letter for Zealands glepaglutide intended to treat short bowel syndrome.

Quality, Data Issues at Mylan Facility in India

[ Price : $8.95]

FDA warns a Viatris Mylan drug manufacturing facility in Pradesh, India, about CGMP violations involving quality and data issues.

Boxed Warning for Veozah Liver Injury

[ Price : $8.95]

FDA adds a liver injury Boxed Warning to labeling for Astellas menopause hot flash drug Veozah.

Lexicon Dropping Zynquista After CRL

[ Price : $8.95]

Lexicon stops development of its diabetes drug Zynquista that received an FDA complete response letter.

Hologic BioZorb Marker Recall Class 1: FDA

[ Price : $8.95]

FDA says a Hologic 3/2024 recall correction of BioZorb Markers was Class 1.